Palliative Therapies for Congenital Heart Disease with Ductus Dependent Pulmonary Circulation

Shi-Min Yuan

doi:10.1055/s-0043-116017

Zeitschrift für Geburtshilfe und Neonatologie, Table of Contents

Z Geburtshilfe Neonatol 2017; 221(06): 272-275
DOI: 10.1055/s-0043-116017

Review

Palliative Therapies for Congenital Heart Disease with Ductus Dependent Pulmonary Circulation

Shi-Min Yuan

¹Department of Cardiothoracic Surgery, The First Hospital of Putian, Teaching Hospital, Fujian Medical University, Putian, China

› Author Affiliations

Abstract

In neonates, the management of ductus dependent pulmonary circulation is challenging. There have been three palliative therapies for this lesion: the modified Blalock-Taussig shunt, ductal stenting and prostaglandin E infusions, for maintaining the ductal patency before definite operations. Debates remain with regard to the indications and disadvantages of three palliative therapies. The aim of this article is to give a brief review of these three palliative therapies.

Key words

congenital heart defects - ductus arteriosus - pulmonary circulation.

Full Text

References

References
1 Gournay V. The ductus arteriosus: physiology, regulation, and functional and congenital anomalies. Arch Cardiovasc Dis 2011; 104: 578-585
2 Habshan FA. Ductal-dependent forms of congenital heart disease: clinical significance of prenatal diagnosis. http://www.sha-conferences.com/files/presentation2011/005004.pdf, Accessed on March 25, 2017
3 Viñals F, Tapia J, Giuliano A. Prenatal detection of ductal-dependent congenital heart disease: how can things be made easier?. Ultrasound Obstet Gynecol 2002; 19: 246-249
4 Kouatli A. Ductus arteriosus dependent congenital heart disease. www.sha-education.com/sites/all/sha23_presentations/27-1-2012/007002.pdf Accessed on March 25, 2017
5 Hussain A, Al-Zharani S, Muhammed AA. et al. Midterm outcome of stent dilatation of patent ductus arteriosus in ductal-dependent pulmonary circulation. Congenit Heart Dis 2008; 3: 241-249
6 Yuan SM, Shinfeld A, Raanani E. The Blalock-Taussig shunt. J Card Surg 2009; 24: 101-108
7 Metras D, Kreitmann B, Riberi A. et al. A simple approach to takedown of a modified Blalock shunt. Ann Thorac Surg 1992; 53: 912-913
8 Küçük M, Özdemir R, Karaçelik M. et al. Risk factors for thrombosis, overshunting and death in infants after modified Blalock-Taussig shunt. Acta Cardiol Sin 2016; 32: 337-342
9 McMullan DM, Permut LC, Jones TK. et al. Modified Blalock-Taussig shunt versus ductal stenting for palliation of cardiac lesions with inadequate pulmonary blood flow. J Thorac Cardiovasc Surg 2014; 147: 397-401
10 Yun SW. Congenital heart disease in the newborn requiring early intervention. Korean J Pediatr 2011; 54: 183-191
11 Akaike T, Minamisawa S. Prostaglandin E-mediated vascular remodeling of the ductus arteriosus and ductus-dependent congenital heart diseases. J Mol Genet Med 2016; 10: e109 10.4172/1747-0862.1000e109
12 Gruzdev A, Nguyen M, Kovarova M. et al. PGE₂ through the EP4 receptor controls smooth muscle gene expression patterns in the ductus arteriosus critical for remodeling at birth. Prostaglandins Other Lipid Mediat 2012; 97: 109-119
13 Aydın B, Dilli D, Zenciroğlu A. et al. Intussusception in a term newborn with duct-dependent congenital heart disease. Dicle Tıp Dergisi 2013; 40: 105-108
14 Huang FK, Lin CC, Huang TC. et al. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation. Pediatr Neonatol 2013; 54: 102-106
15 Ustün N, Dilli D, Zenciroğlu A. et al. Long-term prostaglandin E1 use in newborns with duct-dependent congenital heart diseases: one year experience of a tertiary neonatal intensive care unit in Turkey. Anadolu Kardiyol Derg 2013; 13: 732-734
16 Silove ED, Roberts DG, de Giovanni JV. Evaluation of oral and low dose intravenous prostaglandin E₂ in management of ductus dependent congenital heart disease. Arch Dis Child 1985; 60: 1025-1030
17 Kobayashi N, Aida N, Nishimura G. et al. Acute gastric outlet obstruction following the administration of prostaglandin: an additional case. Pediatr Radiol 1997; 27: 57-59
18 Sivakumar K, Bhagyavathy A, Coelho R. et al. Longevity of neonatal ductal stenting for congenital heart diseases with duct-dependent pulmonary circulation. Congenit Heart Dis 2012; 7: 526-533
19 Santoro G, Gaio G, Capozzi G. et al. Fate of hypoplastic pulmonary arteries after arterial duct stenting in congenital heart disease with duct-dependent pulmonary circulation. JACC Cardiovasc Interv 2015; 8: 1626-1632
20 Buys DG, Brown SC, Greig C. Stenting the arterial duct: practical aspects and review of outcomes. SAHeart 2013; 10: 514-519
21 Alwi M, Choo KK, Latiff HA. et al. Initial results and medium-term follow-up of stent implantation of patent ductus arteriosus in duct-dependent pulmonary circulation. J Am Coll Cardiol 2004; 44: 438-445